Clinical Trial Update: A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated bevacizumab with chemotherapy or Tarceva (erlotinib) for recurrent or refractory non-small cell lung cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Tarceva (erlotinib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small-Cell Lung Carcinoma, Neoplasm Recurrence, Local | Phase 2 | Status: COMPLETED